Skip to main content
OpenTrials

Clinical trial condition

Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)

Explore clinical trials studying Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL). Study availability and eligibility vary by location and protocol.

1 public trial 1 recruiting study
Refine in advanced search Browse all conditions

Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL) trial results

Recruiting

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

NCT06149286

Conditions
Disease Attributes, Hemic and Lymphatic Diseases, Immune System Diseases, +15 more
Locations
  • David Geffen School of Medicine at UCLA Los Angeles, California, United States
  • Boca Raton Clinical Research (BRCR) Global Plantation, Florida, United States
  • Indiana University and Comprehensive Cancer Center Indianapolis, Indiana, United States
  • Hattiesburg Clinic Hattiesburg, Mississippi, United States
View all 169 locations
View Trial Details

Related conditions